GlassScriptPhysician profile
Lynn H Ratner
NPI 1891749255
$4,338.75
in general payments reported to CMS, 2019-2025
51 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,957 · 2020: $773 · 2021: $1,200 · 2022: $410.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $390.23 | 2019-2021 | |
| Genentech USA, INC. | $335.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $329.53 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $312.52 | 2019-2022 | |
| Lilly USA, LLC | $247.24 | 2019-2020 | |
| Seagen INC. | $211.74 | 2019-2021 | |
| Incyte Corporation | $210.77 | 2019-2022 | |
| Celgene Corporation | $195.29 | 2019-2022 | |
| Pfizer INC. | $158.35 | 2019-2020 | |
| Janssen Biotech, INC. | $156.77 | 2019-2022 | |
| Daiichi Sankyo INC. | $154.65 | 2020 | |
| Puma Biotechnology, INC. | $141.96 | 2019-2021 | |
| Kite Pharma, INC. | $136.12 | 2020-2022 | |
| Rigel Pharmaceuticals, INC. | $133.85 | 2019 | |
| Octapharma USA, INC. | $115.37 | 2019 |
Show all 51 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Ratner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.